However, empagliflozin was able to improve the risk of incident or worsening nephropathy regardless of ACE inhibitor/ARB use, and the risk of acute renal failure with ACE inhibitor/ARB use tended to be lower in patients also taking empagliflozin (for patients on ACE inhibitors/ARBs, acute renal failure rates were 5.4% and 5.9% in empagliflozin-treated patients versus 7% in the placebo group). This evidence concerns the gene ACE and kidney disorder.